PRMT5 and melanoma: Scientists from the Sanford Burnham Prebys Medical Discovery Institute found that combined treatment with PRMT5 inhibitors and PD-1 inhibitors successfully enhanced the response to antitumor immunity by regulating methylation of interferon-γ (IFN-γ)-inducible protein 16 (IFI16) and its murine homolog IFI204, which are components of cGAS/STING, and by inhibiting transcription of the nucleotide-binding oligomerization domain-like receptor family caspase recruitment domain containing 5 (NLRC5) gene in melanoma [46].